Here we report a new modality for targeting the ERK DRS in vivo using the 1,2,4-triazol-3-one chassis, BI-78D3 (Fig. 1a), which disrupts the formation of ERK-protein complexes to affect BRAF-mutant tumor growth. The gene discussed is MAPK1; the disease is neoplasm.